

Libretto Consortium, sponsored by the Gordon and Betty Moore Foundation, and receiving personal fees from Medicalis; receiving patent royalties from Medicalis for radiology decision support software; chairing the US Food and Drug Administration Safety and Innovation Act workgroup, which has advised the US Food and Drug Administration, the Federal Communications Commission, and the Office of the National Coordinator for Health Information Technology including mobile technology; and serving as a member of the Health Information Technology policy committee.

1. Misra S. Happtique's recent setback shows that health app certification is a flawed proposition. <http://www.imedicalapps.com/2014/01/happtiques-setback-future-app-certification/>. Accessed June 18, 2014.
2. Apple's venture into mobile medical applications: a game changer? <http://seekingalpha.com/article/2267553-apples-venture-into-mobile-medical-applications-a-game-changer>. Accessed June 18, 2014.
3. PatientsLikeMe website. Data for good. <http://www.patientslikeme.com/research/dataforgood>. Accessed June 18, 2014.
4. PsyberGuide website. Product list. <http://psyberguide.org/product-listing/>. Accessed June 18, 2014.
5. Chan SR, Torous J, Hinton L, Yellowlees P. Mobile tele-mental health: increasing applications and a move to hybrid models of care. *Healthcare*. 2014;2(2):220-223.

CORRECTION

Incorrect Data in a Table: In the Grand Rounds report entitled "Resistant Hypertension: A Review of Diagnosis and Management" published in the June 4, 2014, issue of *JAMA* (2014;311[21]:2216-2224. doi:10.1001/jama.2014.5180), an incorrect dose range was presented in Table 2. In the Lisinopril row, the dosing range should be "5-80 mg/d." This article was corrected online.

Guidelines for Letters

Letters discussing a recent *JAMA* article should be submitted within 4 weeks of the article's publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the *JAMA* article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at <http://jama.com/public/InstructionsForAuthors.aspx>. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment and the ICMJE Form for Disclosure of Potential Conflicts of Interest are required before publication. Letters should be submitted via the *JAMA* online submission and review system at <http://manuscripts.jama.com>. For technical assistance, please contact jama-letters@jamanetwork.org.

Section Editor: Jody W. Zylke, MD, Deputy Editor.